Financials data is unavailable for this security.
View more
Year on year Hikma Pharmaceuticals PLC grew revenues 9.77% from 2.88bn to 3.16bn while net income improved 88.95% from 190.00m to 359.00m.
| Gross margin | 45.88% |
|---|---|
| Net profit margin | 11.47% |
| Operating margin | 19.30% |
| Return on assets | 7.38% |
|---|---|
| Return on equity | 15.93% |
| Return on investment | 11.18% |
More ▼
Cash flow in USDView more
In 2024, cash reserves at Hikma Pharmaceuticals PLC fell by 17.00m. However, the company earned 564.00m from its operations for a Cash Flow Margin of 17.87%. In addition the company used 381.00m on investing activities and also paid 188.00m in financing cash flows.
| Cash flow per share | 1.82 |
|---|---|
| Price/Cash flow per share | 10.89 |
| Book value per share | 7.63 |
|---|---|
| Tangible book value per share | 3.81 |
More ▼
Balance sheet in USDView more
| Current ratio | 1.14 |
|---|---|
| Quick ratio | 0.6456 |
| Total debt/total equity | 0.5654 |
|---|---|
| Total debt/total capital | 0.3601 |
More ▼
Growth rates in USD
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 5.95% and 88.00%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 2.38% |
|---|---|
| Div growth rate (5 year) | 10.29% |
| Payout ratio (TTM) | 49.30% |
| EPS growth(5 years) | -4.29 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 87.82 |
More ▼
